Promising data for zenocutuzumab in patients with advanced NRG1-positive cholangiocarcinoma were shown according to researchers at Dana-Farber.
CME|Podcasts|April 28, 2026
Medical Crossfire®: Optimizing ESR1 Mutation Detection and Next-Generation Endocrine Therapy Integration in HR+/HER2– Breast Cancer
Thanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts V.K. Gadi, MD, PhD; Neil M. Iyengar, MD; and Heather McArthur, MD; discuss advances in breast cancer treatment, endocrine resistance and mutations, and emerging targeted therapies for early-stage and metastatic disease.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate recent clinical trial data on emerging oral SERDs to inform individualized therapeutic decision-making in HR+/HER2– breast cancer.
- Develop multidisciplinary strategies to effectively manage treatment-related adverse events associated with oral SERD therapies in HR+/HER2– breast cancer.
Acknowledgment of Educational Grant Support
This activity is supported by educational grants from Genentech, Inc; Lilly; and Stemline Therapeutics, Inc.
Chair:
V.K. Gadi, MD, PhD
Professor of Clinical Medicine
Division of Hematology and Oncology
University of Illinois Cancer Center
Director, Medical Oncology
University of Illinois College of Medicine
Chicago, IL
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Daiichi Sankyo, Genentech, Gilead Sciences, Hologic, Novartis, Pfizer, Stemline Therapeutics; Grant/Research Funding: Agendia, AstraZeneca, Gilead Sciences, GlaxoSmithKline, Illumina, Novartis; Stock: Tempus
Faculty:
Neil M. Iyengar, MD
Associate Professor, Department of Hematology and Medical Oncology
Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology
Director, Cancer Survivorship Services
Emory University School of Medicine
Atlanta, GA
Disclosures: Consultant/Advisor: Arvinas, AstraZeneca, BD Life Sciences, Daiichi Sankyo, Genentech/Roche, Gilead, Menarini-Stemline, Novartis, Pfizer, Puma, Seagen, TerSera Therapeutics; Speaker: Cardinal Health, Curio Sciences, DAVA Oncology, IntrinsiQ Health; Editorial Position: npj Breast Cancer, Oncology®; Equity/Ownership: Complement Theory, Bettering Company; Research Support (to institution): American Cancer Society, Breast Cancer Research Foundation, Conquer Cancer Foundation, Kat’s Ribbon of Hope, National Cancer Institute/National Institutes of Health; Contracted Research: Novartis, SynDevRx
Heather McArthur, MD, MPH
Professor, Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, TX
Disclosures: Consultant: Amgen, Arvinas, AstraZeneca, Bristol Myers Squibb, Calithera, Celgene, Daiichi Sankyo, Eli Lilly, Genentech/Roche, Immunomedics, Merck, OBI Pharma, Peregrine, Pfizer, Puma, Seattle Genetics, Spectrum Pharmaceuticals, Syndax Pharmaceuticals, TapImmune; Grant/Research Support: Bristol Myers Squibb, BTG, MedImmune/AstraZeneca, Merck
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on emerging oral SERD therapies, endocrine-resistant disease, and novel breast cancer treatments, go to
Release Date
April 28, 2026
Expiration Date
April 28, 2027
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Related to this article
In a Roswell Park study, changes focused on standardization of care and donor selection, contributing to a 1-year overall survival rate of 92.6%.
A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Sylvester cancer researchers became wildland firefighters themselves to study, from the inside, cancer risks tied to the job.
A Dana-Farber team developed an artificial intelligence method that designs proteins to recognize and hold specific drug molecules.
Shane Lloyd, MD, MHS, and Christos Vaklavas, MD, were selected as new Huntsman Cancer Institute Translational Scholars for their leadership in bridging laboratory discoveries with clinical innovation.
Trending on OncLive
1
Adagrasib Plus Cetuximab Misses OS, PFS End Points in Pretreated KRAS G12C–Mutated CRC
2
Phase 1 Data Highlight Potential Utility for In Vivo CAR T-Cell Therapy in R/R Myeloma
3
AI Finds New Applications in Oncologic Surgery, Drug and Biomarker Screening, and Clinical Trial Design
4
FDA Issues CRL to Orviglance for Liver Metastasis Imaging in Patients With Severe Kidney Impairment
5